Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
63 hedge funds and large institutions have $47.5M invested in Stemline Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 9 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 21
5% less funds holding
Funds holding: 66 → 63 (-3)
25% less capital invested
Capital invested by funds: $63.4M → $47.5M (-$15.9M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $57K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.32M |
| 2 |
B
Bailard
Foster City,
California
|
+$463K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$334K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$244K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$531K |
| 2 |
Millennium Management
New York
|
-$444K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$261K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$253K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$141K |
STML Hedge Fund Activity: Q1 2016 in Review
63 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2016, worth a combined $47.5M — down 25% from $63.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of STML and 6 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 22 added.
The largest buyer was Franklin Resources, adding an estimated $1.32M. The largest seller was Fidelity Investments, cutting an estimated $531K.
- 63 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2016, down from 66 in Q4 2015.
- Funds reported $47.5M of Stemline Therapeutics, Inc. stock for Q1 2016, down 25% quarter-over-quarter.
- 6 funds opened new Stemline Therapeutics, Inc. positions in Q1 2016 and 9 closed out, a net change of -3 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q1 2016 was Franklin Resources, an estimated $1.32M added.
- The largest Stemline Therapeutics, Inc. seller in Q1 2016 was Fidelity Investments, an estimated $531K sold.
Based on aggregated 13F filings for Q1 2016.